<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817633</url>
  </required_header>
  <id_info>
    <org_study_id>213348</org_study_id>
    <secondary_id>4020-01-001</secondary_id>
    <nct_id>NCT02817633</nct_id>
  </id_info>
  <brief_title>A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)</brief_title>
  <official_title>A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tesaro, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing&#xD;
      protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1&#xD;
      consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the&#xD;
      recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of&#xD;
      TSR-022.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2016</start_date>
  <completion_date type="Anticipated">October 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a multi-center, open-label, first-in-human Phase 1 study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of participants achieving dose limiting toxicity (DLTs)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, treatment emergent adverse events (TAEs), TEAEs leading to death and immune-related adverse events (irAEs)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of participants with clinically significant changes in laboratory parameters, vital signs, electrocardiogram (ECG) findings, Eastern Cooperative Oncology Group (ECOG) status, physical examination and use of concomitant medications</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anti-TSR-022, anti-TSR-042 and anti-TSR-033 antibodies</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: ORR by RECIST v 1.1 and immune-related RECIST (irRECIST)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Duration of response (DOR) by RECIST v 1.1 and irRECIST</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Disease control rate (DCR) by RECIST v 1.1 and irRECIST</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Progression-free survival (PFS) by RECIST v 1.1 and irRECIST</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Maximum plasma concentration (Cmax) of TSR-022 when administered as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: Cmax of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: Cmax of TSR-022 when administered in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: Cmax of TSR-022 when administered in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: Cmax of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: Cmax of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1g: Cmax of TSR-022 in combination with TSR-042, pemetrexed and cisplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1h: Cmax of TSR-022 in combination with TSR-042, pemetrexed, and carboplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of TSR-022</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Minimum plasma concentration (Cmin) of TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: Cmin of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: Cmin of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: Cmin of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: Cmin of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: Cmin of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1g: Cmin of TSR-022 in combination with TSR-042, pemetrexed and cisplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1h: Cmin of TSR-022 in combination with TSR-042, pemetrexed and carboplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmin of TSR-022</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Area under the concentration × time curve from time 0 to infinity AUC (0-inf) of TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: AUC (0-inf) of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: AUC (0-inf) of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: AUC (0-inf) of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: AUC (0-inf) of in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: AUC (0-inf) of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1g: AUC (0-inf) of TSR-022 in combination with TSR-042, pemetrexed and cisplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1h: AUC (0-inf) of TSR-022 in combination with TSR-042, pemetrexed and carboplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC (0-inf) of TSR-022</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Area under the concentration × time curve at steady state (AUCss) of TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: AUCss of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: AUCss of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: AUCss of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: AUCss of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: AUCss of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1g: AUCss of TSR-022 in combination with TSR-042, pemetrexed and cisplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1h: AUCss of TSR-022 in combination with TSR-042, pemetrexed and carboplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUCss of TSR-022</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Maximum plasma concentration at steady state (Cmax,ss) of TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: Cmax,ss of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: Cmax,ss of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: Cmax,ss of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: Cmax,ss of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: Cmax,ss of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1g: Cmax,ss of TSR-022 in combination with TSR-042, pemetrexed and cisplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1h: Cmax,ss of TSR-022 in combination with TSR-042, pemetrexed and carboplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax,ss of TSR-022</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Minimum plasma concentration at steady state (Cmin,ss) of TSR-022 022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: Cmin,ss of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: Cmin,ss of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: Cmin,ss of of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: Cmin,ss of of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: Cmin,ss of of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1g: Cmin,ss of TSR-022 in combination with TSR-042, pemetrexed and cisplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1h: Cmin,ss of TSR-022 in combination with TSR-042, pemetrexed and carboplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmin,ss of TSR-022</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Area under the concentration time curve from time 0 to last assessment (AUC 0-last) of TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: AUC (0-last) of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: AUC (0-last) of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: AUC (0-last) of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: AUC (0-last) of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: AUC (0-last) of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1g: AUC (0-last) of TSR-022 in combination with TSR-042, pemetrexed and cisplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1h: AUC (0-last) of TSR-022 in combination with TSR-042, pemetrexed and carboplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC (0-last) of TSR-022</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Clearance (CL) of TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: CL of TSR-022 in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: CL of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: CL of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: CL of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: CL of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1g: CL of TSR-022 in combination with TSR-042, pemetrexed and cisplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1h: CL of TSR-022 in combination with TSR-042, pemetrexed and carboplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: CL of TSR-022</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Volume of distribution (Vz) of TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: Vz of TSR-022 and in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: Vz of TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: Vz of TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e : Vz of TSR-022 in combination with TSR-042 in participants not previously treated with anti-PD-(L)1 therapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: Vz of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1g: Vz of TSR-022 in combination with TSR-042, pemetrexed and cisplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1h: Vz of TSR-022 in combination with TSR-042, pemetrexed and carboplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Vz of TSR-022</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Terminal half life (1/2) TSR-022 as monotherapy</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: t1/2 of TSR-022 and in combination with nivolumab</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c: t1/2 TSR-022 in combination with TSR-042</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1d: t1/2 TSR-022 in combination with TSR-042 and TSR-033</measure>
    <time_frame>Pre-dose, 0.5, 1.0, 1.5, 2.5, 3, 24, 48, 96, 168,336 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1e: t1/2 TSR-022 in combination with TSR-042 in participants not previously treated with PD-(L)1</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1f: t1/2 of TSR-022 in combination with TSR-042 and docetaxel</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1g: t1/2 of TSR-022 in combination with TSR-042, pemetrexed and cisplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1h: t1/2 of TSR-022 in combination with TSR-042, pemetrexed and carboplatin</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: t1/2 of TSR-022</measure>
    <time_frame>Pre-dose, 0.25, 0.5 hour post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Anticipated">369</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Part 1a: TSR-022 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1b: TSR-022 in combination with nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1c: TSR-022 in combination with TSR-042</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1d: TSR-022 in combination with TSR-042 and TSR-033</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1e: TSR-022 with TSR-042 (not previously treated with anti-programmed death ligand [PD-{L}]1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1f: TSR-022 in combination with TSR-042 and Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1g: TSR-022 in combination with TSR-042, pemetrexed, and cisplatin.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1h: TSR-022 in combination with TSR-042, pemetrexed, and carboplatin.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort A Melanoma-TSR-022 as monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort A Melanoma-TSR-022 with TSR-042</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2:CohortB Non-small cell lung cancer-TSR-022-monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2:CohortB Non-small cell lung cancer-TSR-022 with TSR-042</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2:CohortC Colorectal cancer-TSR-022 as monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2:CohortC Colorectal cancer-TSR-022 with TSR-042</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort D-TIM-3 selected non-small cell lung cancer (NSCLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TSR-022</intervention_name>
    <description>TSR-022 will be administered.</description>
    <arm_group_label>Part 1a: TSR-022 monotherapy</arm_group_label>
    <arm_group_label>Part 1b: TSR-022 in combination with nivolumab</arm_group_label>
    <arm_group_label>Part 1c: TSR-022 in combination with TSR-042</arm_group_label>
    <arm_group_label>Part 1d: TSR-022 in combination with TSR-042 and TSR-033</arm_group_label>
    <arm_group_label>Part 1e: TSR-022 with TSR-042 (not previously treated with anti-programmed death ligand [PD-{L}]1)</arm_group_label>
    <arm_group_label>Part 1f: TSR-022 in combination with TSR-042 and Docetaxel</arm_group_label>
    <arm_group_label>Part 1g: TSR-022 in combination with TSR-042, pemetrexed, and cisplatin.</arm_group_label>
    <arm_group_label>Part 1h: TSR-022 in combination with TSR-042, pemetrexed, and carboplatin.</arm_group_label>
    <arm_group_label>Part 2: Cohort A Melanoma-TSR-022 as monotherapy</arm_group_label>
    <arm_group_label>Part 2: Cohort A Melanoma-TSR-022 with TSR-042</arm_group_label>
    <arm_group_label>Part 2: Cohort D-TIM-3 selected non-small cell lung cancer (NSCLC)</arm_group_label>
    <arm_group_label>Part2:CohortB Non-small cell lung cancer-TSR-022 with TSR-042</arm_group_label>
    <arm_group_label>Part2:CohortB Non-small cell lung cancer-TSR-022-monotherapy</arm_group_label>
    <arm_group_label>Part2:CohortC Colorectal cancer-TSR-022 as monotherapy</arm_group_label>
    <arm_group_label>Part2:CohortC Colorectal cancer-TSR-022 with TSR-042</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab will be administered.</description>
    <arm_group_label>Part 1b: TSR-022 in combination with nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TSR-042</intervention_name>
    <description>TSR-042 will be administered.</description>
    <arm_group_label>Part 1c: TSR-022 in combination with TSR-042</arm_group_label>
    <arm_group_label>Part 1d: TSR-022 in combination with TSR-042 and TSR-033</arm_group_label>
    <arm_group_label>Part 1e: TSR-022 with TSR-042 (not previously treated with anti-programmed death ligand [PD-{L}]1)</arm_group_label>
    <arm_group_label>Part 1f: TSR-022 in combination with TSR-042 and Docetaxel</arm_group_label>
    <arm_group_label>Part 1g: TSR-022 in combination with TSR-042, pemetrexed, and cisplatin.</arm_group_label>
    <arm_group_label>Part 1h: TSR-022 in combination with TSR-042, pemetrexed, and carboplatin.</arm_group_label>
    <arm_group_label>Part 2: Cohort A Melanoma-TSR-022 with TSR-042</arm_group_label>
    <arm_group_label>Part 2: Cohort D-TIM-3 selected non-small cell lung cancer (NSCLC)</arm_group_label>
    <arm_group_label>Part2:CohortB Non-small cell lung cancer-TSR-022 with TSR-042</arm_group_label>
    <arm_group_label>Part2:CohortC Colorectal cancer-TSR-022 with TSR-042</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TSR-033</intervention_name>
    <description>TSR-033 will be administered.</description>
    <arm_group_label>Part 1d: TSR-022 in combination with TSR-042 and TSR-033</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel will be administered.</description>
    <arm_group_label>Part 1f: TSR-022 in combination with TSR-042 and Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>Part 1g: TSR-022 in combination with TSR-042, pemetrexed, and cisplatin.</arm_group_label>
    <arm_group_label>Part 1h: TSR-022 in combination with TSR-042, pemetrexed, and carboplatin.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Part 1g: TSR-022 in combination with TSR-042, pemetrexed, and cisplatin.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Part 1h: TSR-022 in combination with TSR-042, pemetrexed, and carboplatin.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Participant is at least 18 years of age.&#xD;
&#xD;
          -  Female participants of childbearing potential must have a negative serum or urine&#xD;
             pregnancy test within 72 hours prior to the date of the first dose of study medication&#xD;
             or be of non-childbearing potential.&#xD;
&#xD;
          -  Participant has an ECOG performance status of less than or equal to (&lt;=)1.&#xD;
&#xD;
          -  Participant has adequate organ function.&#xD;
&#xD;
        Inclusion Criteria for Participants in Part 1 and Part 2 Cohorts A, B, and C:&#xD;
&#xD;
          -  Participant with advanced or metastatic solid tumor who meets the requirements for the&#xD;
             part of the study/cohort he/she will participate in, as follows:&#xD;
&#xD;
          -  Part 2: Histologically proven advanced (unresectable) or metastatic solid tumor that&#xD;
             is measurable by computed tomography (CT) or magnetic resonance imaging (MRI) per&#xD;
             RECIST version 1.1 criteria&#xD;
&#xD;
          -  Inclusion Criteria for Participants in Part 2 Cohort D&#xD;
&#xD;
          -  Participants with advanced or metastatic NSCLC that is measurable by CT or MRI per&#xD;
             RECIST version 1.1 criteria and meet the following criteria:&#xD;
&#xD;
          -  NSCLC histology includes squamous or non-squamous cell carcinoma.&#xD;
&#xD;
          -  Participants have received no more than 2 prior lines of therapy, which must include a&#xD;
             platinum-based chemotherapy (for example [e.g.], cisplatin, carboplatin) and an&#xD;
             anti-PD-(L)1 antibody.&#xD;
&#xD;
          -  Participants must have documented radiographic progression by RECIST version 1.1&#xD;
             criteria on prior anti-programmed cell death protein (PD)-1 or anti-PD-(L)1 therapy.&#xD;
&#xD;
          -  Biopsies - If a participant has had a biopsy prior to entering the 35-day screening&#xD;
             period and within approximately 12 weeks of study treatment, that biopsy may be&#xD;
             accepted as the Baseline fresh biopsy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  History of Grade greater than or equal to (&gt;=)3 immune-related AE with prior&#xD;
             immunotherapy, with the exception of non-clinically significant lab abnormalities.&#xD;
&#xD;
          -  Participant has known uncontrolled central nervous system (CNS) metastases and/or&#xD;
             carcinomatous meningitis.&#xD;
&#xD;
          -  Participant has a known additional malignancy that progressed or required active&#xD;
             treatment within the last 2 years. Participants with a prior or concurrent malignancy&#xD;
             whose natural history or treatment does not have the potential to interfere with the&#xD;
             safety or efficacy assessment of the investigational regimen may be included only&#xD;
             after discussion with the Medical Monitor.&#xD;
&#xD;
          -  Participant is considered a poor medical risk due to a serious, uncontrolled medical&#xD;
             disorder, nonmalignant systemic disease or active infection requiring systemic&#xD;
             therapy.&#xD;
&#xD;
          -  Participant is pregnant or breastfeeding, or expecting to conceive children within the&#xD;
             projected duration of the study, starting with the Screening Visit through 150 days&#xD;
             after the last dose of study treatment.&#xD;
&#xD;
          -  Participant has a diagnosis of immunodeficiency or is receiving systemic steroid&#xD;
             therapy or any other form of immunosuppressive therapy within 7 days prior to the&#xD;
             first dose of study treatment.&#xD;
&#xD;
        Exclusion Criteria for Participants in Part 2 Cohort D&#xD;
&#xD;
          -  A participant with negative (as determined by Central Testing Lab) or unevaluable&#xD;
             TIM-3 expression from tissue obtained prior to study entry will not be eligible for&#xD;
             the study.&#xD;
&#xD;
          -  Participant has received prior therapy as defined below:&#xD;
&#xD;
          -  Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent that resulted in&#xD;
             permanent discontinuation due to an AE.&#xD;
&#xD;
          -  Prior treatment with an anti-lymphocyte activation gene (LAG)-3 or anti-TIM-3.&#xD;
&#xD;
          -  Radiologic or clinical progression &lt;= 8 weeks after initiation of prior anti-PD-1 or&#xD;
             anti-PD-L1 antibody.&#xD;
&#xD;
          -  Participants with known epidermal growth factor receptor (EGFR) mutation, anaplastic&#xD;
             lymphoma kinase (ALK) translocation, or ROS1 mutation.&#xD;
&#xD;
          -  Participant has received a vaccine other than a vaccine against severe acute&#xD;
             respiratory syndrome (SARS)-coronavirus 2 (CoV-2) infection (&quot;Coronavirus Disease&#xD;
             2019&quot; [COVID-19]) within 7 days of planned start of study therapy. The use of all&#xD;
             COVID-19 vaccines is allowed, with the exception of COVID-19 vaccines using the&#xD;
             recombinant adenoviral vector platform within 30 days of planned start of study&#xD;
             therapy. If a COVID-19 vaccine using this platform is to be administered within 30&#xD;
             days of planned start of study therapy, this must first be discussed with and approved&#xD;
             by the Sponsor's Medical Monitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Cente</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sunil Sharma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Edward F McClay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Haresh S. Jhangiani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Antoni Ribas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Peter D Boasberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Edward F McClay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Merrill K Shum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Allen L. Cohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Karl Lewis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Allen L. Cohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gerald Falchook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Patricia M Lorusso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chul Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Judy S Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zeynep Eroglu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ragini Kudchadkar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nagla Karim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard S Siegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hedy Kindler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard S Siegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mohammed Milhem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Chesney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pikeville</city>
        <state>Kentucky</state>
        <zip>41501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher C. Croot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>John M Wallmark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Justin Gainor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Martin E Gutierrez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjay Goel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Janice Mehnert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Bajor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rex B Mowat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph Fiorillo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213-2982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2584</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Diwakar Davar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Theodore G Gourdin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Erika Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jason M. Melear</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos R Becerra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Richey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Julio Peguero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy Yap</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Donald A. Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503-1298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Habib M. H. Ghaddar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Donald A. Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weslaco</city>
        <state>Texas</state>
        <zip>78596</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Habib M. H. Ghaddar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>8613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander I. Spira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ying Zhuo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Puyallup</city>
        <state>Washington</state>
        <zip>98373</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Veatch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Veatch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nataliya Uboha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <state>Navarra</state>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eduardo Castañón Álvarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Enriqueta Felip</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joaquim Bosch Barrera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>María Jové Casulleras</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Delvys Rodríguez Abreu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Victor Moreno García</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Luis Paz Ares</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Valentina Boni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Manuel Trigo Pérez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eduardo Castañón Álvarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Desamparados Roda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TSR-022</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Cobolimab</keyword>
  <keyword>Advanced solid tumors</keyword>
  <keyword>Metastatic solid tumors</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>PD-1</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Melanoma</keyword>
  <keyword>TSR-033</keyword>
  <keyword>TSR-042</keyword>
  <keyword>Dostarlimab</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

